Abstract
Multiple myeloma (MM) bone disease is a major contributor to the morbidity and mortality of MM patients due to pathological fractures. The MM cells interact with the cells of the bone microenvironment to both generate bone lesions as a result of enhanced induction of osteoclastogenesis and prevent reactive new bone formation to heal the lesions by repressing osteoblast activity. The MM stimulated osteoclasts (OCLs) not only generate bone lesions, but also interact with the myeloma cells to promote the proliferation and survival of the MM cells through the generation of interleukin-6 (IL-6), osteopontin, fibroblast activation protein, BAFF, APRIL, and annexin II. These MM-supportive OCL products present therapeutic opportunities. Further, the enhanced bone resorption by OCLs releases immobilized growth factors from the bone matrix that both support the MM cells and further stimulate OCL differentiation in a vicious cycle. Hence, targeting osteoclast activity may inhibit myeloma growth. Therefore, bisphosphonates have been investigated for their anti-tumor affects. The MM cells increase osteoclast activity both directly and by stimulation of microenvironmental production of RANKL, MIP-1α, TNF-α and interleukins IL-1b, IL-3 and IL-6. These are therefore also possible therapeutic targets to inhibit myeloma bone disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32:290–292
Melton LJ 3rd, Kyle RA, Achenbach SJ et al (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20:487–493
Taube T, Beneton MN, McCloskey EV et al (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192–198
Yaccoby S, Wezeman MJ, Henderson A et al (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64:2016–2023
Abe M, Hiura K, Wilde J et al (2004) Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104:2484–2491
Ge Y, Zhan F, Barlogie B et al (2006) Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol 133:83–92. doi:10.1111/j.1365-2141.2006.05976.x
Pennisi A, Li X, Ling W et al (2009) Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol 145:775–787. doi:10.1111/j.1365-2141.2009.07696.x
Tanaka Y, Abe M, Hiasa M et al (2007) Myeloma cell–osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13:816–823. doi:10.1158/1078-0432.CCR-06-2258
Abe M, Kido S, Hiasa M et al (2006) BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20:1313–1315. doi:10.1038/sj.leu.2404228
D’Souza S, Shiozawa Y, Galson DL et al (2009) Annexin II and Annexin II receptor interactions enhance multiple myeloma growth in the bone marrow microenvironment. In: The IX international meeting on cancer induced bone disease, Arlington, VA (Abstract)
Bao H, Jiang M, Zhu M et al (2009) Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 90:177–185. doi:10.1007/s12185-009-0356-8
Takahashi S, Reddy SV, Chirgwin JM et al (1994) Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem 269:28696–28701
Menaa C, Devlin RD, Reddy SV et al (1999) Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. J Clin Invest 103:1605–1613
Cole SP, Pinkoski MJ, Bhardwaj G et al (1992) Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 65:498–502
Shinar DM, Schmidt A, Halperin D et al (1993) Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ. J Bone Miner Res 8:403–414
Vishwanatha JK, Chiang Y, Kumble KD et al (1993) Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14:2575–2579
Emoto K, Sawada H, Yamada Y et al (2001) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21:1339–1345
Claudio JO, Masih-Khan E, Tang H et al (2002) A molecular compendium of genes expressed in multiple myeloma. Blood 100:2175–2186. doi:10.1182/blood-2002-01-0008
Zimmermann U, Woenckhaus C, Pietschmann S et al (2004) Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 445:368–374. doi:10.1007/s00428-004-1103-4
Sharma MR, Koltowski L, Ownbey RT et al (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146–156. doi:10.1016/j.yexmp.2006.03.003
Shiozawa Y, Havens AM, Jung Y et al (2008) Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 370:370–380. doi:10.1002/jcb.21835
Li F, Chung H, Reddy SV et al (2005) Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res 20:1161–1167
Costes V, Portier M, Lu ZY et al (1998) Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 103:1152–1160
Choi SJ, Cruz JC, Craig F et al (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96:671–675
Giuliani N, Colla S, Rizzoli V (2004) New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 32:685–691
Lee JW, Chung HY, Ehrlich LA et al (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103:2308–2315
Gunn WG, Conley A, Deininger L et al (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24:986–991
Ehrlich LA, Roodman GD (2005) The role of immune cells and inflammatory cytokines in Paget’s disease and multiple myeloma. Immunol Rev 208:252–266
Sezer O, Heider U, Jakob C et al (2002) Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99:4646–4647
Giuliani N, Colla S, Sala R et al (2002) Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100:4615–4621
Pearse RN, Sordillo EM, Yaccoby S et al (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581–11586
Menu E, Asosingh K, Van Riet I et al (2004) Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 33:111–119. doi:10.1016/j.bcmd.2004.04.012
Epstein J, Yaccoby S (2005) The SCID-hu myeloma model. Methods Mol Med 113:183–190. doi:10.1385/1-59259-916-8:183
Oba Y, Lee JW, Ehrlich LA et al (2005) MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33:272–278
Vallet S, Raje N, Ishitsuka K et al (2007) MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 110:3744–3752. doi:10.1182/blood-2007-05-093294
Menu E, De Leenheer E, De Raeve H et al (2006) Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 23:291–300. doi:10.1007/s10585-006-9038-6
Wei S, Kitaura H, Zhou P et al (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282–290. doi:10.1172/JCI23394
Lam J, Takeshita S, Barker JE et al (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481–1488. doi:10.1172/JCI11176
Nakamura I, Jimi E (2006) Regulation of osteoclast differentiation and function by interleukin-1. Vitam Horm 74:357–370. doi:10.1016/S0083-6729(06)74015-8
Sati HI, Greaves M, Apperley JF et al (1999) Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 104:350–357
Tsimberidou AM, Waddelow T, Kantarjian HM et al (2003) Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res 27:375–380. doi:S0145212602000826 [pii]
Lust JA, Lacy MQ, Zeldenrust SR et al (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84:114–122. doi:10.4065/84.2.114
Merico F, Bergui L, Gregoretti MG et al (1993) Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 92:27–31
Barton BE, Mayer R (1989) IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells. J Immunol 143:3211–3216
Solary E, Guiguet M, Zeller V et al (1992) Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol 39:163–171
Sati HI, Apperley JF, Greaves M et al (1998) Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 101:287–295
Abildgaard N, Glerup H, Rungby J et al (2000) Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64:121–129
Roodman GD, Kurihara N, Ohsaki Y et al (1992) Interleukin 6. A potential autocrine/paracrine factor in Paget’s disease of bone J Clin Invest 89:46–52
Palmqvist P, Persson E, Conaway HH et al (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169:3353–3362
Karadag A, Oyajobi BO, Apperley JF et al (2000) Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol 108:383–390
Anderson KC, Jones RM, Morimoto C et al (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73:1915–1924
Russell RG, Watts NB, Ebetino FH et al (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759. doi:10.1007/s00198-007-0540-8
Corey E, Brown LG, Quinn JE et al (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295–306
Hiraga T, Williams PJ, Ueda A et al (2004) Zoledronic acid inhibits visceral metastases in the 4 T1/luc mouse breast cancer model. Clin Cancer Res 10:4559–4567. doi:10.1158/1078-0432.CCR-03-0325
Koto K, Horie N, Kimura S et al (2009) Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 274:271–278. doi:10.1016/j.canlet.2008.09.026
Guenther A, Gordon S, Tiemann M et al (2010) The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 126:239–246. doi:10.1002/ijc.24758
Yaccoby S, Pearse RN, Johnson CL et al (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278–290
Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482–492
Radl J, Croese JW, Zurcher C et al (1985) Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5 T2 multiple myeloma. Cancer 55:1030–1040
Brown HK, Holen I (2009) Anti-tumour effects of bisphosphonates–what have we learned from in vivo models? Curr Cancer Drug Targets 9:807–823
Baulch-Brown C, Molloy TJ, Yeh SL et al (2007) Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 31:341–352. doi:10.1016/j.leukres.2006.07.018
Corso A, Ferretti E, Lunghi M et al (2005) Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104:118–125. doi:10.1002/cncr.21104
Nefedova Y, Landowski TH, Dalton WS (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17:1175–1182. doi:10.1038/sj.leu.2402924
Azab AK, Azab F, Blotta S et al (2009) RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 114:619–629. doi:10.1182/blood-2009-01-199281
Denoyelle C, Hong L, Vannier JP et al (2003) New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 88:1631–1640. doi:10.1038/sj.bjc.6600925
Karabulut B, Erten C, Gul MK et al (2009) Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 33:239–246. doi:10.1016/j.cellbi.2008.11.011
Rachner TD, Singh SK, Schoppet M et al (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109–116. doi:10.1016/j.canlet.2009.06.003
Berenson JR, Lichtenstein A, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group N Engl J Med 334:488–493
Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289–3294. doi:10.1182/blood-2006-05-022962
Kondo H, Mori A (2002) Anti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma 43:919–921
Powles T, Paterson S, Kanis JA et al (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219–3224
Diel IJ, Jaschke A, Solomayer EF et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007–2011. doi:10.1093/annonc/mdn429
Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357–363
Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691. doi:10.1056/NEJMoa0806285
Lipton A (2010) Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res Treat 122(3):627–636
Mhaskar R, Redzepovic J, Wheatley K et al. (2010) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 3:CD003188. doi:10.1002/14651858.CD003188.pub2
Aviles A, Nambo MJ, Neri N et al (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24:227–230. doi:MO:24:2:227 [pii]
Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151. doi:10.1089/jir.2005.25.144
Cackowski FC, Anderson JL, Patrene KD et al (2010) Osteoclasts are important for bone angiogenesis. Blood 115(1):140–149
Kollet O, Dar A, Shivtiel S et al (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657–664. doi:10.1038/nm1417
Azab AK, Runnels JM, Pitsillides C et al (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113:4341–4351. doi:10.1182/blood-2008-10-186668
Caccamo N, Meraviglia S, Scarpa F et al (2008) Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther 8:875–883. doi:10.1517/14712598.8.7.875
Roodman GD (2002) Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17:1921–1925
Sezer O, Heider U, Zavrski I et al (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094–2098
Doran PM, Turner RT, Chen D et al (2004) Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 32:351–359. doi:10.1016/j.exphem.2004.01.006
Rabin N, Kyriakou C, Coulton L et al (2007) A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 21:2181–2191. doi:10.1038/sj.leu.2404814
Hamdy NA (2008) Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc) 44:7–21. doi:10.1358/dot.2008.44.1.1178467
Body JJ, Facon T, Coleman RE et al (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221–1228
Vij R, Horvath N, Spencer A et al (2009) An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol 84:650–656. doi:10.1002/ajh.21509
Henry D, von Moos R, Vadhan-Raj S et al (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 7:12 Abstract.
Munshi N, Tai Y-T (2008) Antibody and other immune-based therapies for myeloma. In: Lonial S (ed) Myeloma therapy: pursuing the plasma cell. Humana Press, Totowa, NJ. doi:10.1007/978-1-59745-564-0
Ara T, Declerck YA (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46:1223–1231. doi:10.1016/j.ejca.2010.02.026
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Galson, D.L., D’Souza, S., Roodman, G.D. (2013). Osteoclasts: Potential Target for Blocking Microenvironmental Support of Myeloma. In: Munshi, N., Anderson, K. (eds) Advances in Biology and Therapy of Multiple Myeloma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4666-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4666-8_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4665-1
Online ISBN: 978-1-4614-4666-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)